Source: International Congress 2014 – Update on lung cancer biology for clinicians



Rating:

Share or cite this content

Citations should be made in the following way:
A. Cortot (Lille, France). EGFR-inhibition: resistance mechanisms and new strategies. International Congress 2014 – Update on lung cancer biology for clinicians

Member's Comments

No comment yet.

Related content which might interest you: When and how to identify resistance mechanisms to targeted therapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015 Reversing glucocorticoid resistance as a new therapeutic strategy Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 Understanding the mechanisms of TKIs: the cycle of inhibition and resistance Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 The effect of new drug-resistance antisense gene on multidrug resistance mechanism of drug-resistant human small cell lung cancer cells Source: Eur Respir J 2007; 30: Suppl. 51, 715s Year: 2007 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Genes, mechanisms and new therapies for asthma Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019 TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011